Table of Contents Author Guidelines Submit a Manuscript

Small Molecule Immunomodulators for Cancer Treatment and Prevention

Call for Papers

Cancer immunotherapy development has so far mainly focused on biological immunotherapeutic agents, including monoclonal antibodies and genetically engineered immune cells. Despite the impressive clinical efficacy of this new generation of immunotherapies, only a limited number of patients respond in the long term to these agents. Many potential therapeutic targets have recently been revealed in tumor microenvironments that are more amenable to intervention using small molecules, either chemically synthesized or isolated from natural sources. Modulating the immune system through a small molecule approach offers advantages that are complementary to and potentially synergistic with the use of biological agents for the treatment and/or prevention of cancer. In addition, small molecules could also serve as chemical probes to discover, characterize, and validate novel receptors and immune signaling pathways that could be exploited as targets for the prevention and/or treatment of cancer.

This special issue is designed to capture the most recent progress on small molecule immunomodulators from basic research to clinical applications.

Potential topics include but are not limited to the following:

  • Generation and characterization of small molecules that are capable of agonizing or antagonizing molecular targets involved in the regulation of immune response to tumor
  • Small molecules with the capability to regulate the expression of protein markers (CTLA-4, PD-1/PD-L1, IDO, etc.) that are associated with immune response to tumor growth
  • Immunomodulatory actions and the preventive and/or therapeutic potential of small molecules produced by human microbiome
  • Assay development for screening chemical libraries to identify small molecule immunomodulators for cancer treatment or prevention
  • Combination study of small molecule immunomodulators with biological immunotherapy (cytokines, monoclonal antibodies, and cell therapies)

Authors can submit their manuscripts through the Manuscript Tracking System at https://mts.hindawi.com/submit/journals/bmri/oncology/smic/.

Submission DeadlineFriday, 22 June 2018
Publication DateNovember 2018

Papers are published upon acceptance, regardless of the Special Issue publication date.

Lead Guest Editor

  • Min He, National Cancer Institute, Rockville, USA

Guest Editors